OBJECTIVES: Randomised-controlled trials have recently proven the efficacy of the interleukin (IL)-6 receptor antagonist tocilizumab (TCZ) in giant cell arteritis (GCA). However, the mechanism of action of IL-6 blockade in this disease is unknown. Moreover, the role of regulatory T (Treg) cells in the pathogenesis of GCA remains underexplored. Given the plasticity of Tregs and the importance of IL-6 in their biology, we hypothesised that TCZ might modulate the Treg response in GCA. We therefore characterised the Treg compartment of patients with GCA treated with TCZ. METHODS: We classified 41 patients with GCA into three groups: active disease (aGCA, n=11), disease remission on corticosteroids (rGCA-CS, n=19) and disease remission on TCZ (rGCA-TCZ, n=11). Healthy controls (HCs) were included for comparison. We determined the frequency, phenotype and function of peripheral blood Tregs. RESULTS: Patients with aGCA demonstrated a hypoproliferating Treg compartment enriched in IL-17-secreting Tregs (IL-17+Tregs). Tregs in patients with aGCA disproportionally expressed a hypofunctional isoform of Foxp3 that lacks exon 2 (Foxp3Δ2). Foxp3Δ2-expressing Tregs coexpressed CD161, a marker commonly associated with the Th17 linage, significantly more often than full-length Foxp3-expressing Tregs. Compared with those of HCs, GCA-derived Tregs demonstrated impaired suppressor capacity. Treatment with TCZ, in contrast to CS therapy, corrected the Treg abnormalities observed in aGCA. In addition, TCZ treatment increased the numbers of activated Tregs (CD45RA-Foxp3high) and the Treg expression of markers of trafficking (CCR4) and terminal differentiation (CTLA-4). CONCLUSIONS: TCZ may exert its therapeutic effects in GCA by increasing the proliferation and activation of Tregs, and by reverting the pathogenic Treg phenotype seen during active disease. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
OBJECTIVES: Randomised-controlled trials have recently proven the efficacy of the interleukin (IL)-6 receptor antagonist tocilizumab (TCZ) in giant cell arteritis (GCA). However, the mechanism of action of IL-6 blockade in this disease is unknown. Moreover, the role of regulatory T (Treg) cells in the pathogenesis of GCA remains underexplored. Given the plasticity of Tregs and the importance of IL-6 in their biology, we hypothesised that TCZ might modulate the Treg response in GCA. We therefore characterised the Treg compartment of patients with GCA treated with TCZ. METHODS: We classified 41 patients with GCA into three groups: active disease (aGCA, n=11), disease remission on corticosteroids (rGCA-CS, n=19) and disease remission on TCZ (rGCA-TCZ, n=11). Healthy controls (HCs) were included for comparison. We determined the frequency, phenotype and function of peripheral blood Tregs. RESULTS:Patients with aGCA demonstrated a hypoproliferating Treg compartment enriched in IL-17-secreting Tregs (IL-17+Tregs). Tregs in patients with aGCA disproportionally expressed a hypofunctional isoform of Foxp3 that lacks exon 2 (Foxp3Δ2). Foxp3Δ2-expressing Tregs coexpressed CD161, a marker commonly associated with the Th17 linage, significantly more often than full-length Foxp3-expressing Tregs. Compared with those of HCs, GCA-derived Tregs demonstrated impaired suppressor capacity. Treatment with TCZ, in contrast to CS therapy, corrected the Treg abnormalities observed in aGCA. In addition, TCZ treatment increased the numbers of activated Tregs (CD45RA-Foxp3high) and the Treg expression of markers of trafficking (CCR4) and terminal differentiation (CTLA-4). CONCLUSIONS:TCZ may exert its therapeutic effects in GCA by increasing the proliferation and activation of Tregs, and by reverting the pathogenic Treg phenotype seen during active disease. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Entities:
Keywords:
DMARDs (biologic); Giant Cell Arteritis; T Cells; Treatment
Authors: Aysefa Doganci; Tatjana Eigenbrod; Norbert Krug; George T De Sanctis; Michael Hausding; Veit J Erpenbeck; El-Bdaoui Haddad; Hans A Lehr; Edgar Schmitt; Tobias Bopp; Karl-J Kallen; Udo Herz; Steffen Schmitt; Cornelia Luft; Olaf Hecht; Jens M Hohlfeld; Hiroaki Ito; Norihiro Nishimoto; Kazuyuki Yoshizaki; Tadamitsu Kishimoto; Stefan Rose-John; Harald Renz; Markus F Neurath; Peter R Galle; Susetta Finotto Journal: J Clin Invest Date: 2005-02 Impact factor: 14.808
Authors: Peter M Villiger; Sabine Adler; Stefan Kuchen; Felix Wermelinger; Diana Dan; Veronika Fiege; Lukas Bütikofer; Michael Seitz; Stephan Reichenbach Journal: Lancet Date: 2016-03-04 Impact factor: 79.321
Authors: Nichole R Blatner; Mary F Mulcahy; Kristen L Dennis; Denise Scholtens; David J Bentrem; Joseph D Phillips; Soo Ham; Barry P Sandall; Mohammad W Khan; David M Mahvi; Amy L Halverson; Steven J Stryker; Anne-Marie Boller; Ashima Singal; Rebekka K Sneed; Bara Sarraj; Mohammed Javeed Ansari; Martin Oft; Yoichiro Iwakura; Liang Zhou; Andreas Bonertz; Philipp Beckhove; Fotini Gounari; Khashayarsha Khazaie Journal: Sci Transl Med Date: 2012-12-12 Impact factor: 17.956
Authors: J Hernández-Rodríguez; M Segarra; C Vilardell; M Sánchez; A García-Martínez; M J Esteban; C Queralt; J M Grau; A Urbano-Márquez; A Palacín; D Colomer; M C Cid Journal: Rheumatology (Oxford) Date: 2003-12-16 Impact factor: 7.580
Authors: Raphaèle Seror; Gabriel Baron; Eric Hachulla; Michel Debandt; Claire Larroche; Xavier Puéchal; François Maurier; Benoît de Wazieres; Thomas Quéméneur; Philippe Ravaud; Xavier Mariette Journal: Ann Rheum Dis Date: 2013-07-29 Impact factor: 19.103
Authors: Meghan E Free; Donna O'Dell Bunch; Julie Anne McGregor; Britta E Jones; Elisabeth A Berg; Susan L Hogan; Yichun Hu; Gloria A Preston; J Charles Jennette; Ronald J Falk; Maureen A Su Journal: Arthritis Rheum Date: 2013-07
Authors: Sarah E Allan; Laura Passerini; Rosa Bacchetta; Natasha Crellin; Minyue Dai; Paul C Orban; Steven F Ziegler; Maria Grazia Roncarolo; Megan K Levings Journal: J Clin Invest Date: 2005-10-06 Impact factor: 14.808
Authors: Iris Lee; Liqing Wang; Andrew D Wells; Martin E Dorf; Engin Ozkaynak; Wayne W Hancock Journal: J Exp Med Date: 2005-04-04 Impact factor: 14.307
Authors: Liang Zhou; Jared E Lopes; Mark M W Chong; Ivaylo I Ivanov; Roy Min; Gabriel D Victora; Yuelei Shen; Jianguang Du; Yuri P Rubtsov; Alexander Y Rudensky; Steven F Ziegler; Dan R Littman Journal: Nature Date: 2008-03-26 Impact factor: 49.962
Authors: J C Henes; H Schulze-Koops; M Witt; H P Tony; F Mueller; M Grunke; M Czihal; T Dörner; F Proft Journal: Z Rheumatol Date: 2018-02 Impact factor: 1.372
Authors: Jianguang Du; Qun Wang; Shuangshuang Yang; Si Chen; Yongyao Fu; Sabine Spath; Phillip Domeier; David Hagin; Stephanie Anover-Sombke; Maya Haouili; Sheng Liu; Jun Wan; Lei Han; Juli Liu; Lei Yang; Neel Sangani; Yujing Li; Xiongbin Lu; Sarath Chandra Janga; Mark H Kaplan; Troy R Torgerson; Steven F Ziegler; Baohua Zhou Journal: Sci Immunol Date: 2022-06-24
Authors: Dan Pugh; Maira Karabayas; Neil Basu; Maria C Cid; Ruchika Goel; Carl S Goodyear; Peter C Grayson; Stephen P McAdoo; Justin C Mason; Catherine Owen; Cornelia M Weyand; Taryn Youngstein; Neeraj Dhaun Journal: Nat Rev Dis Primers Date: 2022-01-06 Impact factor: 65.038
Authors: Sergio Prieto-González; Nekane Terrades-García; Marc Corbera-Bellalta; Ester Planas-Rigol; Chie Miyabe; Marco A Alba; Ariel Ponce; Itziar Tavera-Bahillo; Giuseppe Murgia; Georgina Espígol-Frigolé; Javier Marco-Hernández; José Hernández-Rodríguez; Ana García-Martínez; Sebastian H Unizony; Maria C Cid Journal: RMD Open Date: 2017-12-22